A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
← catalyst calendarNCT07228390 · readout in 198 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
240estimated
Sites
71
Countries
Canada, Germany, Greece +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-13 | actual | When the study began enrolling |
| Primary completion | 2027-03-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-02 | estimated | The whole study's end, after follow-up |
| First posted | 2025-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hidradenitis Suppurativa
Interventions
- Drug: Ritlecitinib — also filed as Investigational Product
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFDifference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo.
measured Week 16
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed